Filter by: Subject

Filter by: Subject

Results Per Page:

Coronavirus disease 2019 (COVID-19) (8)
COVID-19 pandemic (8)
Antimicrobial resistance (AMR) (3)
Antimicrobial stewardship programs (3)
Asthma (3)
Gastro-oesophageal reflux disease (GORD) (3)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (3)
Acute upper respiratory tract infection (2)
Antibiotics (2)
Antimicrobial stewardship (2)
Antimicrobials (2)
Antitussive (2)
Bangladesh (2)
Children (2)
Cough (2)
Early intervention (2)
Expectorant (2)
Guidelines (2)
Hospitals (2)
Hypertension (2)
Mucolytic (2)
N-acetyl cysteine (NAC) (2)
Non-steroidal anti-inflammatory drug (NSAID) (2)
Pain (2)
Pharmacists (2)
Access, watch and reserve (AWaRe) (1)
Acid suppression (1)
Africa (1)
Angiotensin II-receptor blockers (1)
Angiotensin-converting enzyme inhibitors (1)
Antibacterial (1)
Antibiotic stewardship program (ASP) (1)
Antihypertensive agents (1)
Antihypertensive drugs (1)
Antimicrobial consumption (1)
Antimicrobial surveillance (1)
Antiretroviral therapy (ART) (1)
Antiviral (1)
Aspirin (1)
Athletes (1)
Avermectin (1)
AWaRe list of antimicrobials (1)
Awareness (1)
Azithromycin (1)
Beta-lactam (β-Lactam) (1)
Beta-lactamase (β-Lactam) (1)
Bronchodilator (1)
Calcium-channel blockers (1)
Ceftazidimeavibactam (1)
Ceftolozane-tazobactam (1)
Centor score (1)
Chloroquine (1)
Coagulopathy (1)
Cross country learning (1)
Diclofenac (1)
Difficult-to-treat resistant (DTR) (1)
Driving (1)
e-Learning (1)
Endectocide (1)
Enoxaparin (1)
Enterobacterales (1)
Factor Xa (1)
Fixed-dose combination (FDC) (1)
Fixed-dose combination therapy (1)
Global health (1)
Gram-negatives (1)
Group A streptococci (GAS) (1)
Healthcare-associated infections (1)
Heartburn (1)
Hybrid approaches (1)
Hydroxychloroquine (1)
Ibuprofen (1)
Immunomodulatory (1)
Indomethacin (1)
Inflammation (1)
Influenza (1)
Inhaled corticosteroid (1)
Internet platforms (1)
Ivermectin (1)
Long-acting β2-agonist (LABA) (1)